Description: EirGenix Inc. operates as a contract development and manufacturing company in Taiwan and internationally. The company offers cell line development, process development, analytical, quality control, cGMP manufacturing mammalian system and microbial system, and antibody-drug conjugate services. It also provides covid-19 antigen rapid test and CRM197 carrier protein related products. The company was incorporated in 2012 and is based in New Taipei City, Taiwan.
Home Page: www.eirgenix.com
No. 101, Kangning Street
New Taipei City,
Taiwan
Phone:
886 2 7708 0123
Officers
| Name | Title |
|---|---|
| Dr. Lee-Cheng Liu | Founder, Pres, CEO, CSO & Chairman |
| Ms. Hsiu-Chuan Yang | CFO, Head of Accounting Department, VP & Mang. of Corp. Governce |
| Dr. Chih-Jung Chang | VP & COO |
| Dr. Thomas Schulze Ph.D. | Managing Director of EirGenix Europe GmbH |
| Dr. Shang-Chung Ju | Exec. Director & Chief Manufacturing Officer |
| Dr. Ae-Ning Lin | Exec. Director of Analytical Science and Quality Control |
Exchange: TWO
Country: TW
Currency: New Taiwan Dollar (NT$)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 65.6627 |
| Price-to-Book MRQ: | 4.3818 |
| Price-to-Sales TTM: | 25.6417 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 0 |